Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05916560 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
A Phase 1 study of Healthy and Hepatic Insufficiency, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 5
- Study locations
NCT05916560 is a Phase 1 study of Healthy and Hepatic Insufficiency that has completed, run by Eli Lilly and Company. The registered enrollment target is 43 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT05916560, a Phase 1 study of Healthy and Hepatic Insufficiency, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.
Conditions Studied
Interventions
- DRUG LY3437943
Study Locations (5)
Florida
- Accel Research Sites- Clinical Research Unit - DeLand
- Advanced Pharma Clinical Research - Miami
Texas
- American Research Corporation at Texas Liver Institute - San Antonio
- Pinnacle Clinical Research - San Antonio
Arizona
- Arizona Clinical Trials - Chandler - Chandler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-07-13 |
| Est. Completion | 2025-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05916560
The ClinicalTrials.gov registry entry for NCT05916560 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which LY3437943 is the first listed.
NCT05916560 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT05916560 about?
NCT05916560 is a clinical study titled "A Study of LY3437943 in Participants With Impaired and Normal Liver Function". The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability ...
What is the current status of trial NCT05916560?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2023-07-13. Estimated completion is 2025-03-02.
What conditions does trial NCT05916560 study?
This clinical trial studies the following conditions: Healthy, Hepatic Insufficiency.
What interventions are being tested in trial NCT05916560?
The interventions under investigation include: LY3437943 (DRUG).
Who is sponsoring clinical trial NCT05916560?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05916560 being conducted?
This trial has 5 study locations across Arizona, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.